The Company believes that HIVCide?„? could very well result in a Functional Cure for HIV/AIDS, if these preliminary results are confirmed in further animal studies and in human clinical trials. In other words, HIVCide treatment could enable a HIV/AIDS patient to lead a completely disease-free life until an episode of hidden virus awakening from latent reservoirs occurs. HIV hides in immune cells forming latent reservoirs. It is widely believed in the scientific community that if these latent reservoirs could be wiped out then a complete cure for HIV/AIDS is possible.

The Company also detailed that it is now developing a single anti-influenza drug that is expected to be highly effective against all influenzas including swine flu (H1N1/2009), bird flu (H5N1), other pandemic capable highly pathogenic influenza viruses, as well as seasonal influenzas. The Company ™s research over the past year enabled it to combine its separate drug programs for highly pathogenic influenzas, bird flu, and seasonal flu into one drug, FluCide?„?, to treat all influenza variants.

The Company has reported significant progress in its topical nanoviricide eye drops program. This drug is designed to treat most viral infections of the external eye, including adenoviral conjunctivitis (EKC) and herpes keratitis.

The Company also reported that it has successfully added a new anti-HSV drug program to its pipeline this year. The Companys topical anti-herpes drug candidate has already demonstrated greater than 10,000-fold (>99.99%, or >4 logs) reduction in virus quantity in cell culture models of HSV-1 infection. Animal model studies of topical and genital herpes are planned.

We have already established a strong and robust drug pipeline, said Anil R. Diwan, PhD, President of the Company, adding, We now plan to focus on filing our first IND application as early as possible.

nanoviricides/